More about High-Yield Cash Accounts with M1
Brokerage Accounts
Retirement Accounts
Other Accounts
Quotes are delayed by 15 minutes.
1D
1W
1M
3M
6M
YTD
1Y
2Y
5Y
ALL
Market cap
$1.13B
EPS
-0.75
P/E ratio
--
Price to sales
3.99
Dividend yield
--
Beta
0.17404
Previous close
$28.30
Today's open
$28.37
Day's range
$28.31 - $31.10
52 week range
$25.76 - $54.85
show more
CEO
Mark L. Baum
Employees
373
Headquarters
Nashville, TN
Exchange
NASDAQ Global Market
Shares outstanding
37533160
Issue type
Common Stock
Healthcare
Pharmaceuticals
Harrow to Participate in Two Investor Conferences in November
NASHVILLE, Tenn., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced that management will participate in the following investor conferences in November: Craig-Hallum 17 th Annual Alpha Select Conference Format: 1x1 investor meetings Date: Tuesday, November 17, 2026 Location: New York, NY 2026 Jefferies Global Healthcare Conference Format: Presentation and 1x1 investor meetings Date/Time: Wednesday, November 18, 2026 at 8:00 a.m.
GlobeNewsWire • Nov 12, 2026

Harrow Q3 Earnings Call Highlights
Harrow NASDAQ: HROW reported record third-quarter revenue and reaffirmed its full-year sales forecast, but sharply reduced its adjusted earnings outlook as lower-than-expected margins and accelerated spending weighed on profitability.
MarketBeat • Nov 10, 2026

Harrow, Inc. (HROW) Q3 2026 Earnings Call Transcript
Harrow, Inc. ( HROW ) Q3 2026 Earnings Call November 10, 2026 8:00 AM EST Company Participants Michael Biega - Vice President of Investor Relations & Communications Mark Baum - CEO, Chairman of the Board & Founder Andrew Boll - President, CFO & Chief Accounting Officer Patrick Sullivan - Chief Commercial Officer Amir Shojaei - Chief Scientific Officer Conference Call Participants Chase Knickerbocker - Craig-Hallum Capital Group LLC, Research Division Lachlan Hanbury-Brown - William Blair & Company L.L.C., Research Division Steven Seedhouse - Cantor Fitzgerald & Co., Research Division Thomas Shrader - BTIG, LLC, Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division Mayank Mamtani - B.
Seeking Alpha • Nov 10, 2026

Harrow Announces Third Quarter 2026 Financial Results
Third Quarter 2026 and Selected Highlights: Record third quarter revenue of $99.3 million, up 41% sequentially and 39% year over year Branded revenue of $83.5 million, up 62% year over year and approximately 84% of total revenue GAAP net income of $9.8 million, including a $5.0 million litigation settlement gain, compared with a net loss of $17.3 million in the second quarter of 2026 and net income of $1.0 million in the third quarter of 2025 Adjusted EBITDA (a non-GAAP measure) of $21.2 million, compared with $(1.2) million in the second quarter of 2026 and $22.8 million in the third quarter of 2025 Reaffirmed full-year 2026 revenue guidance of $350 million to $365 million; updated full-year 2026 Adjusted EBITDA guidance to more than $40 million, including fourth quarter Adjusted EBITDA of more than $33 million, compared with prior Adjusted EBITDA guidance of $80 million to $100 million Cash and cash equivalents of $75.3 million as of September 30, 2026 A Media Snippet accompanying this announcement is available by clicking on this link. NASHVILLE, Tenn.
GlobeNewsWire • Nov 9, 2026

Harrow (HROW) Q3 Earnings Lag Estimates
Harrow (HROW) came out with quarterly earnings of $0.12 per share, missing the Zacks Consensus Estimate of $0.13 per share. This compares to earnings of $0.33 per share a year ago.
Zacks Investment Research • Nov 10, 2026

Harrow (HROW) Reports Q3 Earnings: What Key Metrics Have to Say
Although the revenue and EPS for Harrow (HROW) give a sense of how its business performed in the quarter ended September 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.
Zacks Investment Research • Nov 10, 2026

Harrow (HROW) Expected to Beat Earnings Estimates: Should You Buy?
Harrow (HROW) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks Investment Research • Nov 2, 2026

Harrow Launches HarrowRx Platform
NASHVILLE, Tenn., Nov. 02, 2026 (GLOBE NEWSWIRE) -- Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, today announced the launch of HarrowRx, a prescribing and access pharmacy platform that enables eyecare professionals to access Harrow's entire portfolio directly within the electronic medical record (EMR) systems they already use.
GlobeNewsWire • Nov 2, 2026

PHIL Partners with Harrow to Power HarrowRx, One Prescribing Destination for Harrow's Eye Care Portfolio
SCOTTSDALE, Ariz.--(BUSINESS WIRE)--PHIL Inc., the technology-powered patient access platform, today announced its partnership with Harrow (Nasdaq: HROW), a leading provider of ophthalmic disease management solutions in North America, to launch HarrowRx, Harrow's new prescribing and access platform. HarrowRx gives eye care providers the ability to e-prescribe Harrow's branded ophthalmic portfolio from one destination within the electronic medical record (EMR) systems they already use, with built.
Business Wire • Nov 2, 2026

Harrow's Top Two Drugs Alone Can Justify Its Current Valuation
Harrow trades at a 52-week low due to management miscommunication and short-term revenue volatility, but its fundamentals remain robust. Vevye and Iheezo, Harrow's flagship drugs, both address large, underpenetrated markets and are positioned for significant growth as coverage expands and pricing stabilizes. Temporary headwinds, including inventory dynamics and coverage transitions, have obscured accelerating prescription trends and pricing tailwinds expected to materialize in H2 and beyond.
Seeking Alpha • Oct 29, 2026

¹ Disclosures

Open an M1 investment account to buy and sell Harrow Inc Com commission-free¹. Build wealth for the long term using automated trading and transfers.